Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium

•The amrubicin/carboplatin combination was active as 1st-line therapy for SCLC.•The median survival (10 months) did not suggest any advantage vs. standard regimens.•Despite prophylactic pegfilgrastim, severe myelosuppression was common.